But will have to do away with SEZ benefits in case of domestic sales

After folding Reliance Petroleum into itself, Reliance Industries Ltd (RIL) is weighing selling fuel refined at the former's Jamnagar refinery, an export-oriented unit located in a special economic zone, in the domestic market.

Under Section 80IB of Special Economic Zone Act, any entity having a facility in an SEZ, which is otherwise treated as an export-oriented unit, can sell the product in the domestic market in case the market for export is not viable.

"The objective of an SEZ isto try and sell maximum in the export market but in case it is not available or viable, the products can also be sold in the domestic market," said a source close to RIL.

Company's two-wheeler sales fell 17% in February

Slowly, the two-wheeler landscape is changing and entry-level bikes appear to be the primary reason for that.

Entry level bikes, that cost for less than Rs 40,000 and typically have engine displacements less than 125cc, now comprise a little over half of the total market.

Hero Honda Motors has been the undisputed leader here. But what has happened over the last few months has surprised everyone, including parts suppliers and analysts: Hero Honda has gone from strength to strength in this segment, taking market share away from close competitor Bajaj Auto and this has led to the latter reporting significant overall sales declines.

Hyderabad-based drugmaker will license and supply 75 generic drugsthat address a $200m market to Pfizer

After trying it out for almost a year, the world's biggest drug-maker Pfizer Inc, has decided to turn copycat in right earnest. And the $50 billion giant will take the help of Hyderabad-based Aurobindo Pharma, an established copycat drug-maker, to make this happen.

The multinational will license 70 generic drugs and 12 sterile injectibles, including penicillins and cephalosporins, which according to industry watchers are valued at over $200 million in sales, from Aurobindo for marketing in the US, and Europe.

That is good news for Aurobindo but may not leave much for Pfizer to smile about, say analysts.

After trying it out for almost a year, the world's biggest drug-maker Pfizer Inc, has decided to turn copycat in right earnest. And the $50 billion giant will take the help of Hyderabad-based Aurobindo Pharma, an established copycat drug-maker, to make this happen. The multinational will license 70 generic drugs and 12 sterile injectibles, including penicillins and cephalosporins, which according to industry watchers are valued at over $200 million in sales, from Aurobindo for marketing in the US, and Europe. That is good news for Aurobindo but may not leave much for Pfizer to smile about, say analysts.

TV Today network, the promoter of Aaj Tak news channel, informed on Tuesday that it would buyback 10 per cent equity from public at Rs 115.

The offer price of Rs 115 is at a premium of 102 per cent to the company's yesterday's closing price Rs 56.95 on the NSE.

The company proposes to buy back a maximum of 47.79 lakh equity shares and a minimum of 2 lakh equity shares from existing shareholders at Rs 115 per share for an aggregate amount of about Rs 29.30 crore.

The buy back would commence on March 16 and would close on July 30, 2009.

Siemens VAI Metals Technologies, one of the world's leading engineering and plant-building companies for the iron and steel industry, has won an order worth euro 200 million from public sector Steel Authority of India Limited (SAIL).

The order is for public sector steel major SAIL's upcoming new steel mill, which will be built at the company's Bhilai unit.

For the latest awarded contract, Siemens VAI will engineer and supply three LD converters with a tapping weight of 180 tons.